Torrent Pharma enters into licensing agreement to manufacture and commercialise generic version of Pfizer Oral COVID-19 Treatment

Torrent Pharmaceuticals Limited has announced that it has signed a
non-exclusive, non-transferable, non-sub licensable, license agreement to use the patents and know-how
in relation to the compound Nirmatrelvir with Medicine Patent Pool for manufacture and commercialisation of the generic version of PAXLOVID™ (product containing the
compound Nirmatrelvir to be co-packaged and co-administered with Ritonavir in 95 low
and middle income countries including India for treatment and/or prevention of COVID-19 caused by SARSCoV-2.

Earlier, MPP had entered into license agreement with PF Prism Holdings B.V. (Pfizer) granting MPP with
the rights to sub-license manufacture and commercialisation rights to sub-licensees.

The oral COVID-19 treatment comprises of Nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the
virus from replicating and ritonavir, which slows down Nirmatrelvir’s breakdown to help it remain in the
body for a longer period at higher concentrations.

Pfizer markets its oral COVID-19 treatment under the name PAXLOVID™, which is authorized by U.S. Food
and Drug Administration (FDA) for Emergency Use Authorisation and the UK Medicines and
Healthcare products Regulatory Agency (MHRA) for the treatment of COVID-19 in patients at high-risk of
progressing to serious illness.